FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045589622> ?p ?o ?g. }

• W2045589622 endingPage "29" @default.
• W2045589622 startingPage "23" @default.
• W2045589622 abstract "Abstract Background The activity of enzalutamide after prior treatment with both abiraterone acetate (abiraterone) and docetaxel has been examined in several retrospective studies. However, limited data are available on the efficacy of enzalutamide following abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). Objective To compare the activity of enzalutamide after abiraterone in docetaxel-experienced and docetaxel-naive mCRPC patients. Design, setting, and participants The British Columbia Cancer Agency Cancer Registry was searched for mCRPC patients who received enzalutamide after prior abiraterone. Clinicopathologic characteristics, confirmed prostate-specific antigen (PSA) response rates (PSA decline ≥50% confirmed ≥3 wk later), and survival data were collected. Outcome measurements and statistical analysis Outcomes on enzalutamide were compared between docetaxel-experienced and docetaxel-naive patients using chi-square for PSA response and log-rank test for time to PSA progression and overall survival (OS). Univariate analysis was performed to identify variables associated with confirmed PSA response on enzalutamide, using either chi-square for categorical variables or logistic regression for continuous variables. Results and limitations A total of 115 patients received enzalutamide after abiraterone: 68 had received prior docetaxel and 47 were docetaxel naive. Median time on enzalutamide was 4.1 mo. Confirmed PSA response rates (22% vs 26%; p =0.8), median time to radiologic/clinical progression (4.6 mo vs 6.6 mo; p =0.6), and median OS (10.6 mo vs 8.6 mo; p =0.2) did not differ significantly between docetaxel-experienced and docetaxel-naive patients. No clinical variables (including prior response to abiraterone) were found to associate significantly with confirmed PSA response to enzalutamide. Conclusions Antitumour activity of enzalutamide following abiraterone was limited in mCRPC patients irrespective of prior docetaxel use. Identifying clinical and molecular factors predictive of response to enzalutamide remains a high priority for future research. Patient summary We looked at the effectiveness of enzalutamide after abiraterone acetate for treatment of advanced prostate cancer. We found that patients who had received docetaxel chemotherapy before abiraterone gained similar benefit from enzalutamide compared with patients who had not received docetaxel. These results suggest that earlier treatment with docetaxel does not have a large impact on the activity of enzalutamide after abiraterone." @default.
• W2045589622 created "2016-06-24" @default.
• W2045589622 creator A5005231494 @default.
• W2045589622 creator A5048928839 @default.
• W2045589622 creator A5075093609 @default.
• W2045589622 creator A5087150696 @default.
• W2045589622 creator A5089306688 @default.
• W2045589622 date "2015-01-01" @default.
• W2045589622 modified "2023-10-18" @default.
• W2045589622 title "Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients" @default.
• W2045589622 cites W1512914561 @default.
• W2045589622 cites W1848444843 @default.
• W2045589622 cites W1884893528 @default.
• W2045589622 cites W1938050263 @default.
• W2045589622 cites W1956657204 @default.
• W2045589622 cites W1965002585 @default.
• W2045589622 cites W1965053172 @default.
• W2045589622 cites W1969202480 @default.
• W2045589622 cites W1980244461 @default.
• W2045589622 cites W1996389184 @default.
• W2045589622 cites W2051049441 @default.
• W2045589622 cites W2066112327 @default.
• W2045589622 cites W2080748037 @default.
• W2045589622 cites W2100115202 @default.
• W2045589622 cites W2112564453 @default.
• W2045589622 cites W2118564089 @default.
• W2045589622 cites W2120012330 @default.
• W2045589622 cites W2121023961 @default.
• W2045589622 cites W2121846636 @default.
• W2045589622 cites W2129442897 @default.
• W2045589622 cites W2130189600 @default.
• W2045589622 cites W2137467802 @default.
• W2045589622 cites W2148643283 @default.
• W2045589622 cites W2148998801 @default.
• W2045589622 cites W2165840390 @default.
• W2045589622 cites W2168063883 @default.
• W2045589622 cites W2205955695 @default.
• W2045589622 cites W2589592541 @default.
• W2045589622 cites W2591139416 @default.
• W2045589622 doi "https://doi.org/10.1016/j.eururo.2014.06.045" @default.
• W2045589622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25018038" @default.
• W2045589622 hasPublicationYear "2015" @default.
• W2045589622 type Work @default.
• W2045589622 sameAs 2045589622 @default.
• W2045589622 citedByCount "136" @default.
• W2045589622 countsByYear W20455896222014 @default.
• W2045589622 countsByYear W20455896222015 @default.
• W2045589622 countsByYear W20455896222016 @default.
• W2045589622 countsByYear W20455896222017 @default.
• W2045589622 countsByYear W20455896222018 @default.
• W2045589622 countsByYear W20455896222019 @default.
• W2045589622 countsByYear W20455896222020 @default.
• W2045589622 countsByYear W20455896222021 @default.
• W2045589622 countsByYear W20455896222022 @default.
• W2045589622 countsByYear W20455896222023 @default.
• W2045589622 crossrefType "journal-article" @default.
• W2045589622 hasAuthorship W2045589622A5005231494 @default.
• W2045589622 hasAuthorship W2045589622A5048928839 @default.
• W2045589622 hasAuthorship W2045589622A5075093609 @default.
• W2045589622 hasAuthorship W2045589622A5087150696 @default.
• W2045589622 hasAuthorship W2045589622A5089306688 @default.
• W2045589622 hasConcept C121608353 @default.
• W2045589622 hasConcept C126322002 @default.
• W2045589622 hasConcept C126894567 @default.
• W2045589622 hasConcept C143998085 @default.
• W2045589622 hasConcept C2775832370 @default.
• W2045589622 hasConcept C2776421732 @default.
• W2045589622 hasConcept C2776551883 @default.
• W2045589622 hasConcept C2776694085 @default.
• W2045589622 hasConcept C2777899217 @default.
• W2045589622 hasConcept C2780192828 @default.
• W2045589622 hasConcept C61367390 @default.
• W2045589622 hasConcept C71924100 @default.
• W2045589622 hasConceptScore W2045589622C121608353 @default.
• W2045589622 hasConceptScore W2045589622C126322002 @default.
• W2045589622 hasConceptScore W2045589622C126894567 @default.
• W2045589622 hasConceptScore W2045589622C143998085 @default.
• W2045589622 hasConceptScore W2045589622C2775832370 @default.
• W2045589622 hasConceptScore W2045589622C2776421732 @default.
• W2045589622 hasConceptScore W2045589622C2776551883 @default.
• W2045589622 hasConceptScore W2045589622C2776694085 @default.
• W2045589622 hasConceptScore W2045589622C2777899217 @default.
• W2045589622 hasConceptScore W2045589622C2780192828 @default.
• W2045589622 hasConceptScore W2045589622C61367390 @default.
• W2045589622 hasConceptScore W2045589622C71924100 @default.
• W2045589622 hasIssue "1" @default.
• W2045589622 hasLocation W20455896221 @default.
• W2045589622 hasOpenAccess W2045589622 @default.
• W2045589622 hasPrimaryLocation W20455896221 @default.
• W2045589622 hasRelatedWork W122177069 @default.
• W2045589622 hasRelatedWork W2147887481 @default.
• W2045589622 hasRelatedWork W2540877368 @default.
• W2045589622 hasRelatedWork W2761727080 @default.
• W2045589622 hasRelatedWork W2783882412 @default.
• W2045589622 hasRelatedWork W2899594694 @default.
• W2045589622 hasRelatedWork W2942985299 @default.
• W2045589622 hasRelatedWork W2977622693 @default.
• W2045589622 hasRelatedWork W2982156914 @default.

• next